

Title: Antifungal Activity of Synthetic Scorpion Venom-derived Peptide Analogues against *Candida albicans*

Journal: International Journal of Peptide Research and Therapeutics

Authors: Sabrina S. Snyder,^a Jeremy W. Gleaton,^a Dickson Kirui,^a Wen Chen,^b and Nancy J. Millenbaugh^{a#}

^aMaxillofacial Injury and Disease Department, Naval Medical Research Unit San Antonio, Joint Base San Antonio-Fort Sam Houston, TX, USA

^bEnvironmental Surveillance Department, Naval Medical Research Unit San Antonio, Joint Base San Antonio-Fort Sam Houston, TX, USA

#Corresponding author: nancy.j.millenbaugh.civ@mail.mil

Supplementary Table S1 Antifungal activity of commercial drugs

		MYA- 2876	ATCC 64124	ATCC 76485	ATCC 200955	CA 494	CA 526	CA 2519
MIC (µg/mL) ^a	Fluconazole	2	>128	0.5	<0.25	0.5	0.5	4
	Amphotericin B	0.125	2	1	16	0.0625	0.5	0.25
	Caspofungin	0.5	0.5	1	1	0.5	0.25	0.25
ATCC designation ^b	Fluconazole	S	R	S	N/A	N/A	N/A	N/A
	Amphotericin B	S	N/A	N/A	R	N/A	N/A	N/A
	Caspofungin	S	R	R	N/A	N/A	N/A	N/A

^aClinical strains were tested in triplicate for a total of two times (N=2), and laboratory strains were tested in triplicate for a total of three times (N=3).

^bDrug resistance indicated as R=Resistant or S=Sensitive according to the ATCC Multidrug-Resistant and Antimicrobial Testing Reference Strains brochure

(<https://www.atcc.org/~media/PDFs/Marketing%20Material/Microbiology/Multidrug-Resistant%20and%20Antimicrobial%20Testing%20Reference%20Strains.ashx>) or strain specific product information at www.ATCC.org.

N/A: Not available.